Qternmet Xr

Hypesthesia, Hypesthesia, Hypesthesia + 13 more
Treatment
6 FDA approvals
20 Active Studies for Qternmet Xr

What is Qternmet Xr

DapagliflozinThe Generic name of this drug
Treatment SummarySaxagliptin is an oral medication used to treat diabetes. It belongs to a class of drugs called DPP-4 inhibitors, which work by helping the body produce more insulin and controlling blood sugar levels. Saxagliptin was approved by the FDA in 2009.
Farxigais the brand name
Qternmet Xr Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Farxiga
Dapagliflozin
2008
19

Approved as Treatment by the FDA

Dapagliflozin, also known as Farxiga, is approved by the FDA for 6 uses such as Type 2 Diabetes Mellitus and Physical Activity .
Type 2 Diabetes Mellitus
Used to treat Type 2 Diabetes Mellitus in combination with Metformin
Physical Activity
Used to treat Exercise in combination with Metformin
Diet
Used to treat Diet in combination with Metformin
Type 2 Diabetes
Used to treat Type 2 Diabetes Mellitus in combination with Metformin
Pharmaceutical Preparations
Used to treat previously treated with drugs in combination with Saxagliptin
inadequate response to monotherapy
Used to treat inadequate response to monotherapy in combination with Saxagliptin

Effectiveness

How Qternmet Xr Affects PatientsSaxagliptin boosts the body's natural hormones GLP-1 and GIP by up to three times their normal levels. It specifically targets the DPP-4 enzyme, making it less likely to cause side effects. Saxagliptin works for 24 hours and helps insulin production from the pancreas. It has an IC50 of 0.5 nmol/L, meaning it won't have a serious effect on the heart's rhythm.
How Qternmet Xr works in the bodySaxagliptin is a medicine used to treat type 2 diabetes. It works by increasing the body's natural hormones, called incretins. These hormones help the body use sugar more efficiently by increasing the amount of insulin in the pancreas and decreasing the amount of sugar released by the liver. Saxagliptin blocks an enzyme called DPP-4, which helps the body make a hormone called GLP-1. GLP-1 helps the pancreas produce more insulin and reduces the amount of sugar from the liver. This helps to lower blood sugar levels and manage type 2 diabetes.

When to interrupt dosage

The amount of Qternmet Xr is contingent upon the recognized condition, including dapagliflozin, Diet and Type 2 Diabetes. The degree of dosage also depends on the approach of administration specified in the table below.
Condition
Dosage
Administration
Physical Activity
, 5.0 mg, 10.0 mg, 2.5 mg
Tablet, film coated - Oral, Tablet, film coated, Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral
Congestive Heart Failure
, 5.0 mg, 10.0 mg, 2.5 mg
Tablet, film coated - Oral, Tablet, film coated, Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral
Chronic Kidney Disease
, 5.0 mg, 10.0 mg, 2.5 mg
Tablet, film coated - Oral, Tablet, film coated, Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral
Kidney Failure
, 5.0 mg, 10.0 mg, 2.5 mg
Tablet, film coated - Oral, Tablet, film coated, Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral
Hypesthesia
, 5.0 mg, 10.0 mg, 2.5 mg
Tablet, film coated - Oral, Tablet, film coated, Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral
Hypesthesia
, 5.0 mg, 10.0 mg, 2.5 mg
Tablet, film coated - Oral, Tablet, film coated, Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral
Hypesthesia
, 5.0 mg, 10.0 mg, 2.5 mg
Tablet, film coated - Oral, Tablet, film coated, Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral
Diet
, 5.0 mg, 10.0 mg, 2.5 mg
Tablet, film coated - Oral, Tablet, film coated, Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral
Cardiovascular Mortality
, 5.0 mg, 10.0 mg, 2.5 mg
Tablet, film coated - Oral, Tablet, film coated, Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral
Heart Failure
, 5.0 mg, 10.0 mg, 2.5 mg
Tablet, film coated - Oral, Tablet, film coated, Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral
decrease in the glomerular filtration rate
, 5.0 mg, 10.0 mg, 2.5 mg
Tablet, film coated - Oral, Tablet, film coated, Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral
Hospitalizations
, 5.0 mg, 10.0 mg, 2.5 mg
Tablet, film coated - Oral, Tablet, film coated, Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral
Pharmaceutical Preparations
, 5.0 mg, 10.0 mg, 2.5 mg
Tablet, film coated - Oral, Tablet, film coated, Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral
inadequate response to monotherapy
, 5.0 mg, 10.0 mg, 2.5 mg
Tablet, film coated - Oral, Tablet, film coated, Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral
Cardiovascular Diseases
, 5.0 mg, 10.0 mg, 2.5 mg
Tablet, film coated - Oral, Tablet, film coated, Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral
Type 2 Diabetes
, 5.0 mg, 10.0 mg, 2.5 mg
Tablet, film coated - Oral, Tablet, film coated, Oral, , Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral

Warnings

Qternmet Xr Contraindications
Condition
Risk Level
Notes
Kidney Failure
Do Not Combine
Renal Insufficiency
Do Not Combine
Acidosis
Do Not Combine
Diabetic Ketoacidosis
Do Not Combine
Kidney Failure
Do Not Combine
Dialysis therapy
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Dapagliflozin may interact with Pulse Frequency
There are 20 known major drug interactions with Qternmet Xr.
Common Qternmet Xr Drug Interactions
Drug Name
Risk Level
Description
Acenocoumarol
Major
The metabolism of Acenocoumarol can be decreased when combined with Dapagliflozin.
Aminophylline
Major
The metabolism of Aminophylline can be decreased when combined with Dapagliflozin.
Amitriptyline
Major
The metabolism of Amitriptyline can be decreased when combined with Dapagliflozin.
Amoxapine
Major
The metabolism of Amoxapine can be decreased when combined with Dapagliflozin.
Anagrelide
Major
The metabolism of Anagrelide can be decreased when combined with Dapagliflozin.
Qternmet Xr Toxicity & Overdose RiskSaxagliptin use can lead to more frequent upper respiratory infection, urinary tract infection, and headaches than patients using a placebo.
image of a doctor in a lab doing drug, clinical research

Qternmet Xr Novel Uses: Which Conditions Have a Clinical Trial Featuring Qternmet Xr?

Currently, there are 197 active studies investigating the potential of Qternmet Xr with Saxagliptin to ameliorate Type 2 Diabetes and improve response to Exercise.
Condition
Clinical Trials
Trial Phases
Chronic Kidney Disease
102 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 4, Phase 3, Early Phase 1
Congestive Heart Failure
183 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 4, Phase 3, Early Phase 1
decrease in the glomerular filtration rate
0 Actively Recruiting
Cardiovascular Mortality
0 Actively Recruiting
Cardiovascular Diseases
0 Actively Recruiting
Type 2 Diabetes
166 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1
Pharmaceutical Preparations
0 Actively Recruiting
Diet
5 Actively Recruiting
Not Applicable, Phase 1
Hospitalizations
1 Actively Recruiting
Not Applicable
Kidney Failure
40 Actively Recruiting
Phase 4, Phase 2, Phase 3, Not Applicable, Phase 1, Early Phase 1
Heart Failure
0 Actively Recruiting
Hypesthesia
4 Actively Recruiting
Not Applicable, Phase 1
Hypesthesia
8 Actively Recruiting
Not Applicable, Phase 1
Hypesthesia
2 Actively Recruiting
Not Applicable
Physical Activity
24 Actively Recruiting
Not Applicable, Phase 1, Phase 2
inadequate response to monotherapy
0 Actively Recruiting

Qternmet Xr Reviews: What are patients saying about Qternmet Xr?

5Patient Review
10/17/2015
Qternmet Xr for Type 2 Diabetes Mellitus
I recently found out that I have diabetes. In the month since my diagnosis, I've been taking this medication and it has helped to keep my sugar levels consistent. The only downside is that it makes me sweat a lot. Otherwise, I'm very happy with it.
5Patient Review
5/16/2017
Qternmet Xr for Type 2 Diabetes Mellitus
Xigduo is a really convenient treatment; only having to take one pill per day. The one downside is that it can make you have to urinate frequently, which can be disruptive if it happens in the middle of the night. But other than that, it's been great for reducing my blood sugar with no noticeable side effects.
5Patient Review
12/1/2021
Qternmet Xr for Type 2 Diabetes Mellitus
I took Xigduo XR 5mg/500mg once a day for about 2years. I had no side effects at all. I was able to loss 90lbs and lowered my A1C to 4.9 at which point my Doc told me to stop taking this drug.
5Patient Review
4/30/2018
Qternmet Xr for Type 2 Diabetes Mellitus
I've only been on Xigduo for a month, but I've already lost 15lbs. My blood sugar levels have lowered and I feel great! The only downside is that I sweat a lot more, but that's a small price to pay for the benefits I've seen so far.
5Patient Review
1/30/2018
Qternmet Xr for Type 2 Diabetes Mellitus
This drug has been extremely effective for me. It's helped me lose a lot of weight and I no longer need to take insulin.
5Patient Review
1/30/2018
Qternmet Xr for Type 2 Diabetes Mellitus
I am so pleased with this drug- it got me off of insulin and I've lost a ton of weight. It's easy to take and really works for me!
5Patient Review
10/17/2015
Qternmet Xr for Type 2 Diabetes Mellitus
This medication has been great for me since I was diagnosed with diabetes. My sugar levels are now much more consistent, and I've even lost weight (15lbs in the first two weeks!). The only downside is that it makes me sweat a lot, but that's a small price to pay for such good results otherwise.
5Patient Review
10/27/2016
Qternmet Xr for Type 2 Diabetes Mellitus
I was really pleased with this medication. It helped me lose weight and lower my A1C without making any other changes to my lifestyle.
5Patient Review
5/16/2017
Qternmet Xr for Type 2 Diabetes Mellitus
Xigduo was easy to take just one tablet/day. The main ingredient is a diuretic, which can be inconvenient in the middle of the night. Otherwise, it is very helpful in reducing blood sugar with literally no side effects except for the frequent urination.
5Patient Review
4/30/2018
Qternmet Xr for Type 2 Diabetes Mellitus
I've only been on Xigduo for a month, and I've already lost 15lbs. My sugars have lowered and I feel great! The only negative is that I sweat quite a lot, but it's worth it for the results.
5Patient Review
12/1/2021
Qternmet Xr for Type 2 Diabetes Mellitus
I took Xigduo XR 5mg/500mg once a day for about 2years. I had no side effects at all. I was able to loss 90lbs and lowered my A1C to 4.9 at which point my Doc told me to stop taking this drug.
5Patient Review
10/27/2016
Qternmet Xr for Type 2 Diabetes Mellitus
I was pleasantly surprised by how well this drug worked. I lost 50 pounds without making any other changes to my lifestyle.
4.7Patient Review
5/18/2017
Qternmet Xr for Type 2 Diabetes Mellitus
I've been taking Xigduo for just over two years now. At first, it was really tough on my stomach; however, after a few weeks my body adjusted and I haven't had any problems since. Not to mention, I've lost over 75lbs and no longer have to inject insulin every day. Plus, my AC1 has been consistently under 5.9. It's a win-win!
4.7Patient Review
5/18/2017
Qternmet Xr for Type 2 Diabetes Mellitus
I've been on Xigduo for a little over two years now. At first, it was really hard on my stomach, but after a few weeks my body adjusted and I stopped having any problems. In that time, I've lost over 75lbs and no longer have to inject insulin every day. Plus, my AC1 has stayed under 5.9 the whole time!
4Patient Review
10/26/2018
Qternmet Xr for Type 2 Diabetes Mellitus
I've only been taking this medication for a few days, so I can't speak to its long-term effects yet. However, I have already noticed some positive changes. My fasting blood sugar was 114 this morning, which is a significant improvement from my average of 205-225. I also experienced some hunger and woke up in the middle of the night last night, but I'm hoping that was just due to adjusting to the new medication and that will go away with time.
4Patient Review
10/26/2018
Qternmet Xr for Type 2 Diabetes Mellitus
I've only been taking this medication for a few days, but I'm already seeing improvements in my fasting sugar levels. I was averaging 205-225 before starting this drug, and now I'm down to 114. Hopefully this trend continues!
3Patient Review
9/11/2022
Qternmet Xr for Type 2 Diabetes Mellitus
While this treatment effectively lowers blood sugar levels, the chronic diarrhea it causes is incredibly disruptive to my quality of life. I'm stopping the medication in hopes of finding something that works better for me.
3Patient Review
9/11/2022
Qternmet Xr for Type 2 Diabetes Mellitus
While this medication does lower blood sugar levels, the trade-off is not worth it for me. I've been dealing with diarrhea every day for over a year now, and it's really taken a toll on my quality of life. I'm going to stop taking it and see if things improve.
2.3Patient Review
6/26/2018
Qternmet Xr for Type 2 Diabetes Mellitus
My muscles always feel so sore and achy. I can't seem to get any relief from this pain.
2.3Patient Review
5/3/2020
Qternmet Xr for Type 2 Diabetes Mellitus
I unfortunately got two different infections after using this treatment for just two weeks.
2.3Patient Review
6/26/2018
Qternmet Xr for Type 2 Diabetes Mellitus
I experienced a lot of muscle pain while taking this medication. It was uncomfortable and at times, debilitating.
2.3Patient Review
5/3/2020
Qternmet Xr for Type 2 Diabetes Mellitus
I got a yeast infection within two weeks of starting this treatment, and then shortly after curing that, I got a urinary tract infection. Now I'm urinating every two hours.
2Patient Review
7/18/2021
Qternmet Xr for Type 2 Diabetes Mellitus
Unfortunately, I had to go to the hospital emergency room three days after taking this drug. I experienced severe constipation and abdominal pain. This drug also suppressed my appetite and lowered my blood sugar levels. Overall, I was very unhappy with the severe adverse side effects and discontinued use of the drug.
2Patient Review
7/18/2021
Qternmet Xr for Type 2 Diabetes Mellitus
Unfortunately, I had to go to the hospital emergency room due to a heart event just three days after taking this drug. I also experienced severe constipation and abdominal pain. This drug suppresses your appetite and lowers blood sugar levels, but the adverse side effects were too much for me so I stopped taking it.
1Patient Review
12/14/2014
Qternmet Xr for Type 2 Diabetes Mellitus
I tried this medication twice and both times had an allergic reaction in the form of a rash. I would not recommend it to anyone.
1Patient Review
4/27/2022
Qternmet Xr for Type 2 Diabetes Mellitus
I experienced such significant hair loss after just two months of use that my hairdresser recommended I speak to a doctor. As a result, I started taking Ozempic instead, which has helped with both the hair loss and other side effects like palpitations and nausea.
1Patient Review
12/14/2014
Qternmet Xr for Type 2 Diabetes Mellitus
I was really disappointed with this medication. I had an allergic reaction to it both times I tried it, even when I wasn't taking any other drugs.
1Patient Review
4/27/2022
Qternmet Xr for Type 2 Diabetes Mellitus
After just two months of using this medication, I experienced such significant hair loss that my hairdresser recommended consulting my doctor. As a result, I was put on Ozempic to combat the side effects I was experiencing, like hair loss, palpitations, and nausea.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about qternmet xr

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Why was Qternmet XR discontinued?

"The reason for the discontinuation of Qternmet XR by the manufacturer is unclear. It is possible that the medication was not popular enough, given the cost."

Answered by AI

What is Xigduo XR used for?

"This medication is made of two drugs, dapagliflozin and metformin. It is used to help regulate blood sugar levels in people who have type 2 diabetes, when combined with a healthy diet and exercise routine. High blood sugar levels can cause a range of problems, including kidney damage, blindness, nerve damage, loss of limbs, and sexual dysfunction."

Answered by AI

What is Qternmet?

"Qternmet XR is a once-daily, oral medicine that consists of the selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor dapagliflozin, the dipeptidyl peptidase-4 (DPP-4) inhibitor saxagliptin, and metformin hydrochloride extended release."

Answered by AI

What is Kombiglyze XR used for?

"KOMBIGLYZE XR is a prescription medicine that contains saxagliptin and metformin hydrochloride. KOMBIGLYZE XR is used with diet and exercise to help control high blood sugar (hyperglycemia) in adults with type 2 diabetes. Your doctor will decide if treatment with both saxagliptin and metformin is right for you."

Answered by AI

Clinical Trials for Qternmet Xr

Image of University of California, Los Angeles in Los Angeles, United States.

Tailored DPP for Prediabetes

17 - 25
All Sexes
Los Angeles, CA
The goal of this study is to enhance reach and uptake of diabetes prevention among young adults, with a focus on recruiting underserved and high-need students who face additional challenges, including food and financial insecurity. The specific aims are: Aim 1 - Evaluate the efficacy of an AYA-tailored version of the UC DPP for mitigating type 2 diabetes risk (i.e., weight change) in a pre/post pilot trial. The investigators hypothesize that the AYA-tailored intervention will be effective at producing 5% weight loss from baseline to program completion (at 9-months). Aim 2 - Assess the feasibility and acceptability of an AYA-tailored version of the UC DPP program. The investigators hypothesize that it will be feasible to recruit the desired number of participants given proposed innovative outreach strategies, and that the AYA-tailored intervention will be deemed acceptable to participants both qualitatively and in regards to their retention in the program at rates similar to the larger UC DPP. The investigators will recruit 80 UCLA undergraduate students. Participants will be asked to complete a brief screening online form to assess eligibility and to collect contact information. The PI and/or Research Assistants (RAs) will reach out to eligible participants to obtain informed consent and enroll them in the pilot trial. The investigators will randomize participants to the tailored DPP cohort vs control cohort. Control participants will be offered the opportunity to participate in the tailored DPP in the following academic year. The tailored DPP intervention will be online and asynchronously. Participants will be asked to complete the intervention lessons on their own time. Each lesson typically takes on average 15 minutes to complete. Control group will receive each intervention materials via e-mail for participants to review on their own time and will receive acceptability surveys. The interventions for the control group will be remote. A research assistant will meet with control participants via Zoom to explain the intervention materials. Control group will receive access to a study habits intervention, alcohol use intervention, and financial literacy intervention. At the end of each quarter (Fall, Winter, and Spring), both control and intervention participants will receive an email with a unique link to a brief REDCap survey to ascertain acceptability of sessions/lessons. Furthermore, participants will complete baseline and 9-month follow-up assessments. Participants will complete a 30 minute questionnaire and height/weight measurements will be collected by a RA. Participants will be asked to self-report weight and physical activity at the end of the fall and winter quarter; data will be collected via brief REDCap survey.
Recruiting
Has No Placebo
University of California, Los AngelesLauren E Wisk, PhD
Image of New York University Langone Health in New York, United States.

GGTA1 KO Thymokidney for Kidney Failure

40 - 70
All Sexes
New York, NY
The purpose of this study is to evaluate the safety and efficacy of the GGTA1 KO Thymokidney in patients with end-stage renal disease (ESRD) who are either not eligible for conventional allogeneic kidney transplantation (Group 1) or are on an Organ Procurement and Transplantation Network (OPTN) kidney transplant waitlist, but are more likely to die or go untransplanted within 5 years than receive a kidney transplant (Group 2). The study consists of xenotransplantation followed by a 24-week Post-transplant Follow-up Period (Part A) to evaluate the efficacy and safety objectives followed by a Long-term Follow-up Period (Part B) to evaluate participant survival, GGTA1 KO Thymokidney survival, and screening for zoonotic infections. Part B will continue for the lifetime of the participant or for 52 weeks following nephrectomy, if required.
Phase 1 & 2
Recruiting
New York University Langone HealthUnited Therapeutics
Have you considered Qternmet Xr clinical trials? We made a collection of clinical trials featuring Qternmet Xr, we think they might fit your search criteria.Go to Trials
Image of The Worship Center Cristian Church in Birmingham, United States.

Black Impact for Heart Health

18+
Male
Birmingham, AL
The goal of this clinical trial is to evaluate the implementation and effectiveness of the Black Impact program-a church-based cardiovascular health (CVH) intervention-in Black men aged 35-70 who are at risk for heart disease, diabetes, obesity, and related conditions. The main questions this study aims to answer are: * Does participation in the Black Impact program improve cardiovascular health metrics (e.g., blood pressure, cholesterol, blood sugar) and health behaviors among Black men at The Worship Center Christian Church (TWC)? * What factors influence the adoption, delivery, and sustainability of the Black Impact program in a faith-based setting? Researchers will compare an immediate-start intervention group and a delayed-start (waitlist control) group to assess both short-term health outcomes and program implementation factors. Participants will: * Attend a 90-minute weekly session for 24 weeks, including 45 minutes of physical activity led by a certified trainer and 45 minutes of health education delivered by trained coaches. * Receive one-on-one support from a community health worker to reduce barriers to care and engage with primary care. * Complete biometric health screenings and surveys at baseline, 12 weeks, and 24 weeks to assess clinical and behavioral outcomes. * Use a smartwatch, blood pressure cuff, and other tools to track progress in real time. * Participate in exit focus groups or interviews to share feedback about the intervention. * A subset of TWC leaders and interventionists (N=15) will also be interviewed to assess implementation, resource needs, and sustainability. This study uses the RE-AIM framework to assess Reach, Effectiveness, Adoption, Implementation, and Maintenance, and aims to inform scalable strategies for improving CVH among Black men in trusted community settings.
Waitlist Available
Has No Placebo
The Worship Center Cristian Church
Have you considered Qternmet Xr clinical trials? We made a collection of clinical trials featuring Qternmet Xr, we think they might fit your search criteria.Go to Trials
Image of University of British Columbia - Okanagan in Kelowna, Canada.

Estrogen and Testosterone for Gender Differences in Physiology

18 - 40
All Sexes
Kelowna, Canada
Due to historical exclusion of females from research, there are gaps in the understanding of female physiology, how it differs from males, and how sex-specific hormones contribute. As a result, many diagnoses and treatments are based on male physiology and may not be appropriate or effective for females. Females consistently experience greater risk and report worse neurological outcomes in many diseases, including stroke, cardiac arrest, and dementia. As research in females progresses, differences between sexes and changes throughout the lifespan (e.g., puberty, menopause) highlight the importance of understanding the effects of sex and sex-specific hormones on the body. The brain is arguably the most important organ in the body, consuming 20% of the body's total energy. Previous research supports higher blood flow to the brain in females, and research in animals suggests hormones such as estrogen, progesterone, and testosterone are responsible. However, it is extremely difficult to isolate these hormones in humans, due to natural fluctuations (i.e., menstrual cycle). Therefore, the investigators plan to explore the direct role of these sex-specific hormones in regulating blood flow to the brain by blocking hormone production in healthy males and females and giving back testosterone and estrogen, respectively. The investigators will then conduct a range of tests to look at blood flow to the brain at rest and during various stressors. This research will provide crucial insight into how males and females differ in regulation of brain blood flow and inform new treatments and therapies to a wide range of brain injuries and diseases, improving outcomes and reducing the sex disparity in clinical pathways.
Waitlist Available
Has No Placebo
University of British Columbia - OkanaganPhilip Ainslie, PhD
Image of Los Angeles General Medical Center in Los Angeles, United States.

Supportive Management for Heart Failure and Methamphetamine Addiction

18+
All Sexes
Los Angeles, CA
Heart failure (HF) affects over 6 million people in the US and is a major cause of both hospital admissions and death. HF has many causes and contributing factors. One of the most aggressive forms of HF is associated with methamphetamine abuse, which has become its own epidemic in the US over the past twenty years. People who use methamphetamine tend to develop HF at a much younger age, with more severe disease and more serious consequences. A recent analysis using nationwide data, methamphetamine use doubled the risk of death or hospitalizations compared to non-users in patients with HF. Thus, methamphetamine users with HF represent a very high-risk group of patients from a healthcare perspective. HF may be reversible in some patients who use methamphetamine if patients can achieve 1) abstain from further methamphetamine use and 2) consistently take all the medications that can improve HF. These two goals are very difficult to achieve in practice, as the care of both methamphetamine addiction and HF requires specialized medical expertise and intensive regular follow up of patients. In general, achievement of one goal is not possible without the other. Patients who use methamphetamine have poor adherence to medical follow-up and therapies, and abstinence from methamphetamine is difficult to maintain. This is further complicated because the current model of HF care does not incorporate treatment for methamphetamine use. The current study proposes to launch a multidisciplinary clinic that treats both HF and methamphetamine use disorder at the same time. The HF care will be led by a cardiologist while the methamphetamine use treatment will be led by a psychiatric clinical pharmacist trained in addiction medicine. State-of-the-art HF care will include optimization of four pillar HF medications. Methamphetamine use treatment will include counseling and incentivized abstinence known as contingency management (CM). The investigators will manage the patients in the clinic for 6 months total. The investigators are interested in demonstrating that this integrated clinic model will result in improved delivery of care for these patients by reporting the rates of successful abstinence from methamphetamine, improved optimization of the four HF medications, and enhanced patient reported quality of life over the 6 months of follow up. The investigators will also collect data on the costs associated with providing this level of care and estimate a range of potential cost-savings.
Waitlist Available
Has No Placebo
Los Angeles General Medical Center (+1 Sites)Tien Ng, PharmD
Have you considered Qternmet Xr clinical trials? We made a collection of clinical trials featuring Qternmet Xr, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security